Urinary Bactericidal Activity of 4 Doses of Levofloxacin Against Fluoroquinolone-Resistant E. Coli
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00376376|
Recruitment Status : Completed
First Posted : September 14, 2006
Last Update Posted : November 27, 2008
Single-dose studies of a fluoroquinolone are indicative of their antimicrobial activity since little accumulation occurs with multiple doses. Single-dose studies have been utilized to determine drug concentrations and time kill activity in serum, urine, and respiratory tissues.
The purpose of this study is to evaluate the Urine Bactericidal Activity (UBA) of levofloxacin (250, 500, 750, and 1000 mg) against FQ-resistant, ESBL positive E. coli isolates. In addition, a susceptibility breakpoint concentration in the urine can also be established for each dose of levofloxacin. Furthermore, urine concentrations and serum pharmacokinetic parameters of levofloxacin can be determined.
|Condition or disease||Intervention/treatment||Phase|
|Healthy Volunteers||Drug: levofloxacin at 250, 500, 750, and 1000 mg doses||Not Applicable|
Subjects: -10 healthy (from medical history) adult male or female volunteers
- Normal body weight (within 20 %)
- Age range: 18-60
- Not taking any other restricted medications (ie. antibiotics)
Drug : all drugs are a single dose given after a 12 hour fast
- 1000 mg.levofloxacin
- 750 mg. levofloxacin
- 500 mg levofloxacin
- 250 mg levofloxacin
Levofloxacin Pharmacokinetic Study:
A serum sample will be obtained prior to and at 1.5 (peak), 4.0, 8.0, 12 (50% of interval) and 24 (100% of interval) hours after each single dose of levofloxacin (6 time points).
Levels will be determined by an HPLC assay.
Urine Pharmacodynamic Study:
A urine sample will be obtained prior to and at 1.5 (peak), 4, 8, 12 (50% of interval), and 24 (100% of interval) hours after a single dose of each dose of levofloxacin.
A urine pH will be run on each sample.
All urine levels will be determined by a validated HPLC assay.
Study Isolates: E. coli (TRUST isolates):
- 0.125 (sensitive)
- 4.0 (intermediate)
- 8.0 (resistant)
- 16.0 (resistant)
- 32.0 (resistant)
- 64.0 (resistant)
This MIC range of E. coli isolates should be able to define a levofloxacin susceptibility breakpoint for urinary pathogens at each dose studied.
Urine Cidal Activity: Urine samples will be tested against each of the study isolates. A maximum urine cidal titer will be determined for each urine. The median titer at each time period (10 subjects) will determine the urine cidal activity.
The duration of cidal activity for each isolate will be determined and plotted. A 12-h duration will be considered the minimum time necessary for prolonged Urine Bactericidal Activity (MIC breakpoints).
Safety: All patients will be monitored for side effects during the study.
|Study Type :||Interventional (Clinical Trial)|
|Enrollment :||10 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Urinary Bactericidal Activity of 4 Doses of Levofloxacin (250, 500, &750, and 1000 mg) Against Fluoroquinolone-Resistant E. Coli|
|Study Start Date :||September 2006|
|Study Completion Date :||November 2006|
- evaluate the Urine Bactericidal Activity (UBA) of different doses and urine levels of levofloxacin against drug-resistant bacteria.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00376376
|United States, Michigan|
|Michigan State University- Dept. of Medicine|
|East Lansing, Michigan, United States, 48824|
|Principal Investigator:||Gary E. Stein, Pharm.D.||Michigan State University|
|Principal Investigator:||Daniel Havlichek, M.D.||Michigan State University|